Pfizer and Moderna companies have recently announced their coronavirus vaccines’ effectiveness this month after extensive research. On November 9, Pfizer had initially announced that its COVID-19 vaccine is 90 percent effective. However, on November 16, Moderna emerged with its announcement, stating its vaccine is 94.5 percent effective for preventing infections.
Why Mordena Currently Outshines Pfizer
Initial trial analysis conducted by Moderna involving 30,000 participants indicates the vaccine’s effectiveness protected people from developing mild and severe coronavirus infections without significant side effects.
Researchers also assessed 95 confirmed coronavirus cases from these participants. Ninety cases of the coronavirus cases were placed on placebo, with the remaining five cases observed in a group receiving a two-dose vaccine. Its conclusion resulted in an approximately 94.5 percent vaccine efficacy.
Currently, medical specialists note it’s not clear about the exact period of the vaccine immunity. Also, they are not sure how people may frequently require regular vaccine injections.
Moreover, Moderna stated that people could refrigerate the coronavirus vaccine for up to 30 days, unlike Pfizer’s, requiring only five days. The vaccine also stabilizes at 36 to 46 degrees Fahrenheit for thirty days. People can also store it for up to six months at minus 4 degrees Fahrenheit. This information contrasts with Pfizer’s vaccine that requires a storage temperature of negative 94 degrees Fahrenheit.
Further reports from the CEO show that the company intends to perform vaccine tests among teenagers, soon followed by children below 12 years.
Also, Moderna seeks FDA authorization for its vaccine once it achieves more safety results this month.
However, despite the promising vaccine technologies from these two companies, the country’s leading infectious illness expert stated that people should not avoid the COVID-19 policies. Therefore, Americans should continue maintaining the proper standards and guidelines as before.
Vaccine Future Production
Additionally, Moderna expects to produce around 20 million vaccine doses to distribute in the country by the end of 2020. The primary goal is to offer adequate COVID-19 vaccine doses to all Americans requiring vaccination by the end of the second quarter of 2021. Also, it expects to release 500 million to 1 billion doses worldwide in 2021.
Additional statistics indicate that the company has supply agreements in the Middle East, North America, and other countries globally. By August, it had already struck a deal with the American government to supply 100 million coronavirus vaccine doses. The government had already financed $955 million towards Moderna’s growth, totaling its investment to $2.48 billion.
Final Thoughts from the Recover about Coronavirus Vaccine
The hope for the research involving the coronavirus epidemic shows some positive results with these two latest developments. The good news comes after so much hype for the lengthy periods required by vaccine research before receiving formal approval. However, people should continue remaining vigilant while still adhering to COVID-19 guidelines such as wearing masks, social distancing, sanitizing, etc.
Let’s continue hoping that as research continues, soon there will be a complete cure for the persistent epidemic virus. Besides, if the epidemic has affected your daily life activities, including your mental health, consider visiting a professional rehab center around you to get the appropriate help or support that addresses your needs.